Jade Biosciences, Inc. (JBIO) – What Are Investment Firms Thinking About This Stock?

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO) have been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $51.75.

A number of equities research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Jade Biosciences in a research note on Friday, September 11th. Wedbush reaffirmed an “outperform” rating and issued a $47.00 price target on shares of Jade Biosciences in a research report on Thursday, October 1st. Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 price target on shares of Jade Biosciences in a research note on Tuesday, August 11th. Wall Street Zen downgraded shares of Jade Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. Finally, BTIG Research increased their price objective on shares of Jade Biosciences from $74.00 to $77.00 and gave the company a “buy” rating in a research report on Monday, August 10th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd bought a new stake in shares of Jade Biosciences during the first quarter valued at approximately $353,000. Quantinno Capital Management LP raised its holdings in Jade Biosciences by 3.6% in the 1st quarter. Quantinno Capital Management LP now owns 30,551 shares of the company’s stock worth $429,000 after acquiring an additional 1,059 shares during the last quarter. Engineers Gate Manager LP bought a new position in Jade Biosciences in the 2nd quarter valued at approximately $503,000. Bank of America Corp DE lifted its position in Jade Biosciences by 2.9% in the 1st quarter. Bank of America Corp DE now owns 38,598 shares of the company’s stock valued at $542,000 after acquiring an additional 1,086 shares in the last quarter. Finally, Maven Securities LTD bought a new position in Jade Biosciences in the 2nd quarter valued at approximately $1,111,000.

Jade Biosciences Stock Down 2.1%

Jade Biosciences stock opened at $14.59 on Tuesday. Jade Biosciences has a twelve month low of $8.36 and a twelve month high of $28.00. The company has a market capitalization of $927.88 million, a P/E ratio of -7.60 and a beta of 1.64. The stock’s 50 day moving average is $17.26 and its 200 day moving average is $19.69.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). As a group, equities analysts expect that Jade Biosciences will post -2.89 EPS for the current year.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for autoimmune and other immune-mediated diseases. The company is building a pipeline of antibody-based therapies designed to modulate the immune system and address significant unmet medical needs.

Jade’s development programs include JDB001, an investigational therapeutic being advanced for potential use in immune-mediated conditions. The company’s product candidates remain in clinical development and have not been approved for commercial use.

Jade Biosciences is headquartered in the United States and conducts its research and development activities through a biotechnology-focused operating model.